Last updated on September 2018

A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma

Brief description of study

This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The Expansion part of the study will evaluate objective response rate and duration of response by modified Response Evaluation Criteria In Solid Tumors (mRECIST) for HCC and Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on independent imaging review (IIR).

Clinical Study Identifier: NCT03006926

Contact Investigators or Research Sites near you

Start Over

Customer Joy Department. EJ

Eisai Trial Site 2
Kashiwa, Japan
  Connect »